Thursday, Apr 20 / 2023
Virtual Meeting
Download for Outlook/Apple Calendar Add to Google Calendar

April Virtual Investor Forum

The forum will feature 20-minute presentations (including Q&A) from a curated selection of exciting start-up companies, all of whom have been carefully selected through our screening processes. You will also see an updated presentation from a past presenting company.


Dionysus Digital Health
Dionysus Digital Health has a platform technology combining state-of-the-art machine learning with the first biomarkers capable of diagnosing hormonal sensitivity.
Entelexo Biotherapeutics
Entelexo Biotherapeutics is unlocking the potential of exosome-based drugs to revolutionize treatments for patients living with autoimmune diseases.
Flyshare
Flyshare and its partners will transition commercial aviation fuel from kerosene to hydrogen. Flyshare will also activate dozens of underutilized airports around the country.
inMotion
InMotion’s tested and patented algorithm (Activity Engine) finally liberates wearable devices to precisely capture motion like never before.
mHeart
mHeart has the first and only comprehensive remote monitoring solution for the cardiac patient providing near real-time, accurate, actionable information which positively impacts patient outcomes, payors, physicians, and hospitals.
Smart Cups, Inc
Smart Cups Technology is the future of consumer products. Their patented printed ingredient technology enables waterless transportation of consumer products, saving space and reducing truck trips.
ARwall
ARwall is an AR technology company that created the first AR display that requires no headset, no goggles, and no smart device. Their spatial imaging technology is four times faster than anything equivalent on the market.
Vikktoria
Vikktoria is a non-advertising B2C marketplace powered by a search engine with an AI-enabled algorithm that brings relevant real-time search and connectivity with 1.3 million lawyers.
CytoRecovery
CytoRecovery has developed a revolutionary cell sorting platform that is faster, generates better cell samples, and is 5 times less expensive than the current market leader.